These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21946550)

  • 1. Aqueous vascular endothelial growth factor and endothelin-1 levels in branch retinal vein occlusion associated with normal tension glaucoma.
    Sin BH; Song BJ; Park SP
    J Glaucoma; 2013 Feb; 22(2):104-9. PubMed ID: 21946550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW
    Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
    Sohn HJ; Han DH; Lee DY; Nam DH
    Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
    Park SP; Ahn JK
    Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion.
    Yasuda S; Kachi S; Ueno S; Ushida H; Piao CH; Kondo M; Terasaki H
    Jpn J Ophthalmol; 2014 May; 58(3):232-6. PubMed ID: 24668132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection.
    Costagliola C; Daniele A; dell'Omo R; Romano MR; Aceto F; Agnifili L; Semeraro F; Porcellini A
    Exp Eye Res; 2013 May; 110():50-4. PubMed ID: 23454098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
    Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POSSIBLE MOLECULAR BASIS OF BEVACIZUMAB THERAPY FOR MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION.
    Noma H; Mimura T; Yasuda K; Shimura M
    Retina; 2016 Sep; 36(9):1718-25. PubMed ID: 26866529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.
    Kaneda S; Miyazaki D; Sasaki S; Yakura K; Terasaka Y; Miyake K; Ikeda Y; Funakoshi T; Baba T; Yamasaki A; Inoue Y
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):2982-8. PubMed ID: 21273540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema.
    Noma H; Mimura T; Yasuda K; Shimura M
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(6):3878-85. PubMed ID: 24894397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.